Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06204302 · ClinicalTrials.gov registry record
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,800
- Enrollment target
NCT06204302: Completed study, sponsored by Bayer.
NCT06204302 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,800 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06204302 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,800 participants
- Enrollment target
Study Summary
This is an observational study in which data will be collected and studied from men with non-metastatic prostate cancer (nmPC) who received their usual treatment with 'androgen receptor inhibitors' (ARIs) including darolutamide, enzalutamide, and apalutamide. Prostate cancer is a common cancer in men that starts in the prostate gland, a male reproductive gland found below the bladder. Non-metastatic means that cancer has not yet spread to other parts of the body. Darolutamide, enzalutamide, and apalutamide are already approved ARIs for nmPC in the United States (US). They work by blocking androgens (male sex hormones including testosterone) from attaching to proteins in cancer cells in the prostate. This helps to slow down the growth of the cancer cells. The participants will receive their treatments as prescribed by their doctors during routine medical care according to the approved product information. Researchers want to know more about the use of ARIs and how they affect men with nmPC in the real world. Researchers will only include men who have not been treated with any new type of medication that blocks the action of male sex hormones. The main purpose of this study is to collect and study information from men with nmPC about: * the length of time they continued treatment with an ARI as prescribed by their doctors. * the length of time from the start of the treatment with an ARI until the cancer spreads to other parts of the body. Data will come from the participants' information stored in a database called Komodo Research Dataset (KRD) in the US. The data collected will be from May 2019 to June 2023. Researchers will only track data of eligible US men with nmPC and will follow them for a minimum of 6 months or until the end of the study.
Interventions
- DRUG Apalutamide
- DRUG Enzalutamide
- DRUG Darolutamide (Nubeqa, BAY1841788)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2024-01-05 |
| Est. Completion | 2024-04-04 |
What the finished NCT06204302 record still lists
NCT06204302 is an observational study that tracks outcomes without assigning an intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Apalutamide is the first listed.
NCT06204302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06204302 about?
NCT06204302 is a clinical study titled "An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States". This is an observational study in which data will be collected and studied from men with non-metastatic prostate cancer (nmPC) who received their usual treatment with 'androgen receptor inhibitors' (ARIs) including darolutamide, enzalutamide, and apalutamide. Prostate cancer is a common cancer in m...
What is the current status of trial NCT06204302?
This trial is currently completed. The enrollment target is 1,800 participants. The study started on 2024-01-05. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT06204302?
The interventions under investigation include: Apalutamide (DRUG), Enzalutamide (DRUG), Darolutamide (Nubeqa, BAY1841788) (DRUG).
Who is sponsoring clinical trial NCT06204302?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI